地西他滨在重症镰状细胞病中的临床疗效。 - Suppr

Clinical effectiveness of decitabine in severe sickle cell disease.

作者信息

Saunthararajah Yogen, Molokie Robert, Saraf Santosh, Sidhwani Seema, Gowhari Michel, Vara Steven, Lavelle Donald, DeSimone Joseph

出版信息

Br J Haematol. 2008 Apr;141(1):126-9. doi: 10.1111/j.1365-2141.2008.07027.x.

DOI:10.1111/j.1365-2141.2008.07027.x

PMID:18324975

Abstract

摘要

相似文献

Clinical effectiveness of decitabine in severe sickle cell disease.地西他滨在重症镰状细胞病中的临床疗效。

Br J Haematol. 2008 Apr;141(1):126-9. doi: 10.1111/j.1365-2141.2008.07027.x.

DNA hypo-methylating agents and sickle cell disease.DNA低甲基化剂与镰状细胞病

Br J Haematol. 2004 Sep;126(5):629-36. doi: 10.1111/j.1365-2141.2004.05064.x.

Decitabine has promising clinical activity in chronic myeloid leukemia.地西他滨在慢性髓性白血病中具有良好的临床活性。

Expert Rev Anticancer Ther. 2002 Dec;2(6):620-1.

Decitabine: development of a DNA methyltransferase inhibitor for hematological malignancies.地西他滨：一种用于血液系统恶性肿瘤的DNA甲基转移酶抑制剂的研发

Curr Opin Investig Drugs. 2003 Dec;4(12):1442-50.

Proteomic analysis identifies differentially expressed proteins in AML1/ETO acute myeloid leukemia cells treated with DNMT inhibitors azacitidine and decitabine.蛋白质组学分析鉴定出 AML1/ETO 急性髓系白血病细胞经 DNMT 抑制剂阿扎胞苷和地西他滨治疗后的差异表达蛋白。

Leuk Res. 2012 May;36(5):607-18. doi: 10.1016/j.leukres.2011.11.024. Epub 2012 Jan 9.

Decitabine: a historical review of the development of an epigenetic drug.地西他滨：一种表观遗传药物研发的历史回顾

Ann Hematol. 2005 Dec;84 Suppl 1(Suppl 1):3-8. doi: 10.1007/s00277-005-0008-x.

Decitabine and sickle cell disease: molecular therapy for a molecular disease.地西他滨与镰状细胞病：针对分子疾病的分子疗法。

Pediatr Hematol Oncol. 2007 Oct-Nov;24(7):465-8. doi: 10.1080/08880010701558188.

Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.地西他滨联合阿克拉霉素/阿糖胞苷治疗难治性急性髓系白血病的临床疗效。

Ann Hematol. 2012 Dec;91(12):1879-86. doi: 10.1007/s00277-012-1550-y. Epub 2012 Aug 16.

Utility of DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromes.DNA 甲基转移酶抑制剂在骨髓增生异常综合征治疗中的应用。

Curr Pharm Des. 2012;18(22):3190-7. doi: 10.2174/1381612811209023190.

Decitabine is an effective treatment of idiopathic myelofibrosis.地西他滨是治疗原发性骨髓纤维化的一种有效疗法。

Br J Haematol. 2009 Apr;145(1):131-2. doi: 10.1111/j.1365-2141.2008.07541.x. Epub 2008 Dec 26.

引用本文的文献

Innovations in Drug Discovery for Sickle Cell Disease Targeting Oxidative Stress and NRF2 Activation-A Short Review.针对氧化应激和NRF2激活的镰状细胞病药物发现创新——简短综述

Int J Mol Sci. 2025 Apr 28;26(9):4192. doi: 10.3390/ijms26094192.

Exploring Novel Strategies to Alleviate Symptoms of β-Globinopathies: Examining the Potential Role of Embryonic ε-globin Induction.探索缓解β-珠蛋白病症状的新策略：探讨胚胎 ε-珠蛋白诱导的潜在作用。

Transfus Med Rev. 2024 Oct;38(4):150861. doi: 10.1016/j.tmrv.2024.150861. Epub 2024 Oct 18.

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.一项低剂量皮下地西他滨治疗骨髓纤维化的多中心 2 期临床试验。

Blood Adv. 2024 Nov 26;8(22):5735-5743. doi: 10.1182/bloodadvances.2024013215.

Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies.DNA 甲基转移酶 1 的流式细胞术作为低甲基化治疗的生物标志物。

Cytometry B Clin Cytom. 2024 Jan;106(1):11-24. doi: 10.1002/cyto.b.22158. Epub 2024 Feb 12.

Pharmacological Induction of Fetal Hemoglobin in β-Thalassemia and Sickle Cell Disease: An Updated Perspective.β地中海贫血和镰状细胞病中胎儿血红蛋白的药理学诱导：最新观点

Pharmaceuticals (Basel). 2022 Jun 16;15(6):753. doi: 10.3390/ph15060753.

Trienone analogs of curcuminoids induce fetal hemoglobin synthesis via demethylation at γ-globin gene promoter.姜黄素类三烯酮类似物通过γ-珠蛋白基因启动子去甲基化诱导胎儿血红蛋白合成。

Sci Rep. 2021 Apr 20;11(1):8552. doi: 10.1038/s41598-021-87738-2.

Sickle cell disease: progress towards combination drug therapy.镰状细胞病：联合药物治疗的进展。

Br J Haematol. 2021 Jul;194(2):240-251. doi: 10.1111/bjh.17312. Epub 2021 Jan 20.

Drug Therapies for the Management of Sickle Cell Disease.用于镰状细胞病管理的药物疗法

F1000Res. 2020 Jun 11;9. doi: 10.12688/f1000research.22433.1. eCollection 2020.

Proteomic Studies for the Investigation of γ-Globin Induction by Decitabine in Human Primary Erythroid Progenitor Cultures.用蛋白质组学研究地西他滨在人原代红系祖细胞培养物中诱导γ-珠蛋白生成的作用

J Clin Med. 2020 Jan 3;9(1):134. doi: 10.3390/jcm9010134.

Advances in new drug therapies for the management of sickle cell disease.镰状细胞病治疗新药疗法的进展。

Expert Opin Orphan Drugs. 2018;6(5):329-343. doi: 10.1080/21678707.2018.1471983. Epub 2018 May 14.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical effectiveness of decitabine in severe sickle cell disease.

作者信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献